RxDoctor Payments Data

Lisa Felsman, MD

Family Medicine · Bristol, INNPI 1740501444

Payments from drug & device makers

$8,751in general payments, 2019–2025

Across 581 payments — averaging $15.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AbbVie$1K
  • AstraZeneca$986
  • Lilly USA, LLC$678
  • Pfizer$641
  • Novo Nordisk$591
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$8,733100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,751 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$119,134
Medicare patients
234
Services billed
2,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter117$123,318
MounjaroTirzepatide79$107,950
OzempicSemaglutide35$77,960
JardianceEmpagliflozin30$35,362
JanuviaSitagliptin Phosphate18$17,211
FarxigaDapagliflozin Propanediol14$15,601
XareltoRivaroxaban16$15,549
Breo ElliptaFluticasone/Vilanterol20$11,786
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$6,825
SymbicortBudesonide/Formoterol Fumarate11$6,617
PremarinEstrogens, Conjugated12$5,988
Dexlansoprazole DrDexlansoprazole20$5,095
Incruse ElliptaUmeclidinium Bromide12$4,280
Levothyroxine Sodium497$4,055
Atorvastatin Calcium627$4,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arexvy$1,042$142,965162 claims
Lilly USA, LLCMounjaro$678$107,95079 claims
Novo NordiskOzempic$591$77,96035 claims
Boehringer IngelheimJardiance$404$35,36230 claims
AstraZenecaFarxiga, Symbicort$986$22,21825 claims
MerckJanuvia$91$17,21118 claims
Johnson & JohnsonXarelto$173$15,54916 claims
PfizerPremarin, Paxlovid$641$7,41724 claims
AbbVieSynthroid$1,036$3,59164 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Bristol

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →